Literature DB >> 3874719

Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy.

R Erttmann, S Bielack, G Landbeck.   

Abstract

Kinetics of 7-hydroxy-methotrexate (7-OH-MTX) excretion after high-dose methotrexate (MTX) (12 g/m2) therapy were monitored in 93 consecutive drug cycles of 19 adolescent patients with osteosarcoma. A reversed-phase HPLC method was used. Serum elimination was found to be monophasic with a mean half-life of 5.5 h. Shortly after the 4-h MTX infusion period 7-OH-MTX levels exceeded those of the parent compound. By 12 h after MTX infusion 7-OH-MTX levels were 16.5 times higher than those of MTX itself. Autostimulation of MTX metabolism leading to enhanced 7-OH-MTX production after repeated drug cycles was not observed. The production of 7-OH-MTX decreased significantly from the first to the last high-dose MTX cycle of the adjuvant chemotherapy protocol.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3874719     DOI: 10.1007/bf00257517

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  11 in total

1.  Significance of the 48-hour plasma level in high-dose methotrexate regimens.

Authors:  C Perez; Y M Wang; W W Sutow; J Herson
Journal:  Cancer Clin Trials       Date:  1978

2.  Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate.

Authors:  H Breithaupt; E Küenzlen
Journal:  Cancer Treat Rep       Date:  1982-09

3.  Metabolism of methotrexate in man after high and conventional doses.

Authors:  K K Chan; M S Nayar; J L Cohen; R T Chlebowski; H Liebman; D Stolinsky; M S Mitchell; D Farquhar
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1980-06

4.  Plasma levels of 7-hydroxymethotrexate after high-dose methotrexate treatment.

Authors:  G Milano; A Thyss; N Renee; M Schneider; M Namer; J L Boublil; C M Lalanne
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  In vitro formation of polyglutamyl derivatives of methotrexate and 7-hydroxymethotrexate in human lymphoblastic leukemia cells.

Authors:  G Fabre; L H Matherly; R Favre; J Catalin; J P Cano
Journal:  Cancer Res       Date:  1983-10       Impact factor: 12.701

6.  Adjuvant chemotherapy in osteosarcoma - effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Preliminary results of the COSS 80 study.

Authors:  K Winkler; G Beron; R Kotz; M Salzer-Kuntschik; J Beck; W Beck; W Brandeis; W Ebell; R Erttmann; U Göbel; W Havers; G Henze; L Hinderfield; P Höcker; A Jobke; H Jürgens; H Kabisch; G Landbeck; P Preusser; G Prindull; W Ramach; J Ritter; J Sekera; J Treuner; G Wüst
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

7.  7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate.

Authors:  S A Jacobs; R G Stoller; B A Chabner; D G Johns
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

8.  Determination of 7-hydroxymethotrexate in human plasma by reversed phase high-performance liquid chromatography.

Authors:  R Erttmann; S Bielack; G Landbeck
Journal:  Oncology       Date:  1986       Impact factor: 2.935

9.  The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy.

Authors:  J Lankelma; E van der Klein; F Ramaekers
Journal:  Cancer Lett       Date:  1980-04       Impact factor: 8.679

10.  Synthesis and biologic evaluation of 7-hydroxymethotrexate, 7-methylaminopterin, and 7-methylmethotrexate.

Authors:  D Farquhar; T L Loo
Journal:  J Med Chem       Date:  1972-05       Impact factor: 7.446

View more
  12 in total

1.  High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients.

Authors:  Laila Holmboe; Anders M Andersen; Lars Mørkrid; Lars Slørdal; Kirsten Sundby Hall
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of breast cancer.

Authors:  V J Wiebe; C C Benz; M W DeGregorio
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

3.  Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate.

Authors:  P Sonneveld; F W Schultz; K Nooter; K Hählen
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  The effects of antibiotics and uricosuric drugs on the renal elimination of methotrexate and 7-hydroxymethotrexate in rabbits.

Authors:  H Iven; H Brasch
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat.

Authors:  E Smeland; R M Bremnes; A Andersen; R Jaeger; T J Eide; N E Huseby; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 6.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

7.  Pharmacokinetics of methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in rats and evidence for the metabolism of MTX to 7-OH-MTX.

Authors:  L Fahrig; H Brasch; H Iven
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Inhibition of 7-hydroxymethotrexate formation by amsacrine.

Authors:  R M Bremnes; E Smeland; N P Willassen; E Wist; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  High-dose 7-hydromethotrexate: acute toxicity and lethality in a rat model.

Authors:  E Smeland; O M Fuskevåg; K Nymann; J S Svendesn; R Olsen; S Lindal; R M Bremnes; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

10.  Differences in methotrexate and 7-hydroxymethotrexate inhibition of folate-dependent enzymes of purine nucleotide biosynthesis.

Authors:  J E Baggott; S L Morgan; W H Vaughn
Journal:  Biochem J       Date:  1994-06-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.